Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved patient outcomes.

Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample.

Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.

Unique Rickman Velocette Cafe Racer. Rare bike to complete any Classic Collection. 500cc Venom motor 1958 fully rebuilt including race magneto, 12 volt electrics with alternator and new clutch.

Adaptive Biotechnologies will present new data on clonoSEQ for MRD assessment at ASCO and EHA conferences. Quiver AI Summary Adaptive Biotechnologies Corporation announced that its clonoSEQ® test ...

Adaptive Biotechnologies has raised its full-year MRD revenue guidance to between $180 million and $190 million, reflecting strong demand and operational efficiency.

Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.

BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps ...

| Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance.

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in ...